The information on this website is intended to provide scientific information about Alkermes products and areas of therapeutic interest. Information may include data on investigational uses of approved or unapproved drugs for which safety and effectiveness have not been established. There is no guarantee that such uses will receive health authority approval and Alkermes does not recommend or suggest use of its medicines in a manner inconsistent with approved labeling.

This section includes selected Alkermes abstracts, posters or oral presentations, which have been accepted for congress presentations in the last 2 years. The content contained in this section is subject to congress copyright permissions.

USPC 2026
US Psych Congress Annual
September 15th – 19th 2026, New Orleans, LA
Explore materials from this congress
PLEASE NOTE: Materials will be available on a rolling basis after individual embargoes are lifted. Audio abstracts are generated using text-to-speech software and contain an audio version of the abstract that was submitted and accepted as part of the official conference materials.
Schizophrenia
POSTER
Inpatient Initiation of the Long-Acting Injectable Antipsychotic Aripiprazole Lauroxil for the Treatment of Acute Exacerbations of Schizophrenia
AUTHOR(S)

Peter J. Weiden, MD,1 Jelena Kunovac, MD, MS,2-4 Shifang Liu, PhD,5 Daniel J. Kim, PhD,5 James A. McGrory, PhD5

View poster
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Olanzapine and Samidorphan Combination For Early and Sustained Treatment of Schizophrenia and Bipolar I Disorder: A Plain Language Summary
AUTHOR(S)

Roger S. McIntyre, MD,1,2  Tarrah Holliday, ARNP, PMHNP-BC,3 Chelsie Monroe, MSN, APN, PMHNP-BC,4 Mark S. Todtenkopf, PhD,5 James A. McGrory, PhD,5 Craig Chepke, MD, DFAPA6,7

View poster
Bipolar Disorder
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Long-Term Safety and Efficacy of Olanzapine/Samidorphan in a Subgroup of Early-in-Illness Patients
AUTHOR(S)

Jacob S. Ballon, MD, MPH,1 Christina Arevalo, MS,2 Shifang Liu, PhD,2 Christoph U. Correll, MD3-7

View poster
Bipolar Disorder
Schizophrenia
Bipolar Disorder
Schizophrenia
POSTER
Acute Care Events Following Initiation of Olanzapine/Samidorphan Among Patients With Schizophrenia or Bipolar I Disorder and Comorbid Alcohol Use Disorder
AUTHOR(S)

Rakesh Jain, MD, MPH,1 Andrew Penn, MS, PMHNP-BC,2 Julie A. Carbray, PhD, PMHNP-BC, PMHCNS-BC, FAAN,3 Madhukar H. Trivedi, MD,4 Alejandro G. Hughes, MPH,5 Noah S. Webb, PhD,5 Kanika Ballani, PharmD, MBA,6 Michael J. Doane, PhD,6 Hemangi R. Panchmatia, MSc,6 Andrew J. Cutler, MD7,8

View poster
Bipolar Disorder
Schizophrenia
Sleep-wake disorders
POSTER
Association Between Depression and Disease Burden in Narcolepsy and Idiopathic Hypersomnia: Patient-Centered Results From the ASPIRE Study
AUTHOR(S)

Craig Chepke,1,2 Michael J. Doane,3 Lindsay Jesteadt,4,5 Kristen McCausland,6 Jane Lazar Tucker,6 Gretchen Murphy,3 Anne Marie Morse,7 David T. Plante8

View poster
Sleep-wake disorders
Schizophrenia
POSTER
Safety and Efficacy of Aripiprazole Lauroxil in an Outpatient Setting After Initiation During Hospitalization for an Acute Exacerbation of Schizophrenia
AUTHOR(S)

Peter J. Weiden, MD,1 Jelena Kunovac, MD, MS,2-4 Shifang Liu, PhD,5 Daniel J. Kim, PhD,5 James A. McGrory, PhD5

View poster
Schizophrenia
Schizophrenia
POSTER
Use of an Aripiprazole Lauroxil Injection Administered Once Every Month, 6 Weeks, or 2 Months in People With Schizophrenia: A Clinician-Focused Summary of Study Data
AUTHOR(S)

Brooke Kempf, PMHNP-BC,1 Julie A. Carbray, PhD, PMHNP-BC, PMHCNS-BC, APRN, FAAN,2 Rebecca Barbee, MSPAS, PA-C, CAQ-Psych,3 Andrew J. Cutler, MD,4,5 Craig Chepke, MD, DFAPA,6,7 Mark S. Todtenkopf, PhD,8 Daniel J. Kim, PhD,8 James A. McGrory, PhD,8 Dave McDonnell, MD,9 Peter J. Weiden, MD10

View poster
Schizophrenia
Schizophrenia
POSTER
Real-World Persistence on Olanzapine/Samidorphan Versus Other Oral Second-Generation Antipsychotics in Patients With Schizophrenia
AUTHOR(S)

Andrew J. Cutler, MD,1,2 Christoph U. Correll, MD,3-7 Rakesh Jain, MD, MPH,8 Craig Chepke, MD,9,10 Hara E. Oyedeji, DNP, PMHNP-BC,11 Alejandro G. Hughes, MPH,12 Noah S. Webb, PhD,12 Michael J. Doane, PhD,13 Hemangi R. Panchmatia, MSc13

View poster
Schizophrenia
Sleep-wake disorders
POSTER
Orexin 2 Receptor Agonists as a Potential Therapeutic Approach to the Treatment of Sleep-Wake Disturbance, Fatigue, and Cognitive Deficit in Neuropsychiatric Disease
AUTHOR(S)

David T. Plante,1 Andrew J. Cutler,2,3 Julie Brooks,4 Ishani Landry,4 Bhaskar Rege,4 Julie Himes,4 Craig Hopkinson,4 and Emmanuel Mignot5

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
Alixorexton Improved Patient-Reported Disease Severity, Cognitive Functioning, and Fatigue in Participants With Narcolepsy Type 1 in the Vibrance-1 Study
AUTHOR(S)

Yves Dauvilliers,1 Ronald R. Grunstein,2,3 Emmanuel Mignot,4 Gert J. Lammers,5,6 David T. Plante,7 Erik Buntinx,8 Rafael del Río Víllegas,9,10 Hailu Chen,11 Craig Hopkinson,11 Bhaskar Rege,11 Julie Himes,11 Michael J. Doane,11 Giuseppe Plazzi12,13

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
REFRESH Real-World Experience in Narcolepsy: Burden of Twice-Nightly Oxybate and Changes in Symptoms and Quality of Life With Extended-Release, Once-Nightly Sodium Oxybate
AUTHOR(S)

Sarah D. Meskill, MD1; Gerard Meskill, MD1; Asim Roy, MD2; Adrian Santamaria, MD3; Robyn Porpiglio, FNP-C4; Oktai Mamedov, MD5; Sally Ibrahim, MD6,7; Omavi Bailey, MD8; Richard K. Bogan, MD9,10; Laura B. Herpel, MD10,11; Matthew Davis, MD12; Jeremy D. McConnell, MD13; Gretchen S. Richards, MS14; Brian Abaluck, MD14; Jennifer Gudeman, PharmD15,a

View poster
Sleep-wake disorders
Sleep-wake disorders
POSTER
Nighttime Symptom Experience and Treatment Challenges: Perspectives From People With Narcolepsy
AUTHOR(S)

Luis E. Ortiz, MD1; Maggie Lavender, MSN, RN, FNP-C2,3; Anne Marie Morse, DO4; Beth Schneider, BA5; Matthew Horsnell, BS6; Dan Liss7; Shawn Kuczenski8; Jennifer Gudeman, PharmD9,a

View poster
Sleep-wake disorders